Overview

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
Phase:
Phase 2
Details
Lead Sponsor:
Noven Therapeutics
Collaborator:
Noven Pharmaceuticals, Inc.
Treatments:
Methylphenidate